GlaxoSmithKline plc (GSK.L) (LON:GSK) Insider Emma Walmsley Acquires 9 Shares of Stock


Share on StockTwits

GlaxoSmithKline plc (GSK.L) (LON:GSK) insider Emma Walmsley bought 9 shares of the stock in a transaction that occurred on Tuesday, January 12th. The shares were bought at an average cost of GBX 1,384 ($18.08) per share, with a total value of £124.56 ($162.74).

Emma Walmsley also recently made the following trade(s):

  • On Wednesday, December 9th, Emma Walmsley bought 9 shares of GlaxoSmithKline plc (GSK.L) stock. The shares were bought at an average cost of GBX 1,403 ($18.33) per share, with a total value of £126.27 ($164.97).
  • On Tuesday, November 10th, Emma Walmsley bought 9 shares of GlaxoSmithKline plc (GSK.L) stock. The shares were bought at an average cost of GBX 1,462 ($19.10) per share, with a total value of £131.58 ($171.91).

GSK stock opened at GBX 1,372.60 ($17.93) on Thursday. The company has a market capitalization of £69.04 billion and a P/E ratio of 10.87. The company has a debt-to-equity ratio of 136.96, a quick ratio of 0.58 and a current ratio of 0.90. GlaxoSmithKline plc has a 52-week low of GBX 1,284 ($16.78) and a 52-week high of GBX 1,857 ($24.26). The business has a 50-day simple moving average of GBX 1,375.77 and a two-hundred day simple moving average of GBX 1,464.86.

The business also recently declared a dividend, which will be paid on Thursday, January 14th. Shareholders of record on Thursday, November 12th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, November 12th. This represents a yield of 1.44%. GlaxoSmithKline plc (GSK.L)’s dividend payout ratio (DPR) is currently 60.17%.

GSK has been the subject of several analyst reports. UBS Group set a GBX 1,440 ($18.81) target price on GlaxoSmithKline plc (GSK.L) and gave the stock a “neutral” rating in a research report on Monday, December 14th. Shore Capital reaffirmed a “sell” rating on shares of GlaxoSmithKline plc (GSK.L) in a research report on Thursday, October 29th. Credit Suisse Group set a GBX 1,580 ($20.64) target price on GlaxoSmithKline plc (GSK.L) and gave the stock a “neutral” rating in a research report on Thursday, October 29th. Barclays reiterated a “sell” rating and set a GBX 1,300 ($16.98) price target on shares of GlaxoSmithKline plc (GSK.L) in a report on Friday, October 30th. Finally, Morgan Stanley reiterated a “neutral” rating and set a GBX 1,665 ($21.75) price target on shares of GlaxoSmithKline plc (GSK.L) in a report on Friday, November 13th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the stock. GlaxoSmithKline plc (GSK.L) has a consensus rating of “Hold” and an average price target of GBX 1,763.63 ($23.04).

About GlaxoSmithKline plc (GSK.L)

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Read More: How to build a Fibonacci channel

Insider Buying and Selling by Quarter for GlaxoSmithKline plc (GSK.L) (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc (GSK.L) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc (GSK.L) and related companies with MarketBeat.com's FREE daily email newsletter.